BCL2 and small cell lung carcinoma: This remodelling of endoplasmic reticulum Ca2+ levels could be therapeutically exploited, as demonstrated in small cell lung cancer cell lines, where a peptide inhibitor of the BCL-2-IP3R interaction enhances the apoptotic effect of navitoclax (ABT-263), a BCL-2/BCL-xL inhibitor [11].